Trials / Completed
CompletedNCT00002154
A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia
Parallel Group, Placebo-Controlled, Tolerability and Safety Study of Thioctic Acid and Deprenyl in HIV Dementia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (planned)
- Sponsor
- The Dana Foundation · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if it is safe and effective to give thioctic acid and deprenyl (selegiline hydrochloride), alone or in combination, to HIV-infected patients who have mild to moderate dementia (a decline in their mental abilities).
Detailed description
Patients are randomized to receive thioctic acid alone, deprenyl alone, thioctic acid/deprenyl, or placebo alone for 10 weeks, after which all patients may receive active drug on an open-label basis. Patients must have seven clinic visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Thioctic acid | |
| DRUG | Selegiline hydrochloride |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00002154. Inclusion in this directory is not an endorsement.